Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical Officer at Chemomab Therapeutics and previously served as VP, Clinical Development and Medical Affairs, Specialty Pharma at Boehringer Ingelheim and VP and Head of Immunology and Dermatology at Novartis in addition to prior roles at Sandoz, Reata Pharmaceuticals, Fibrogen, Facet Biotech, and Schering Plough.
Frankel commented, “I am thrilled to join Nocion as we drive the ongoing Phase 2b refractory chronic cough trial forward to completion. I look forward to working with the team and the scientific community to help realize the vast potential of this platform which can silence nerves that cause the sensation of pain while leaving touch and movement neurons unaffected.”
Nocion CEO Rick Batycky said, “We are delighted to welcome Matthew to the senior management team as we continue the clinical development of taplucainium for chronic cough and the evolution of Nocion’s platform. Matthew brings important expertise and perspective from many years of large pharma medical management experience.”
Read the Nocion Therapeutics press release
